Complying with Massachusetts disclosure regulation will be a challenge
Pharma Compliance Alert, April 1, 2009
Massachusetts’ new disclosure regulation, which goes into effect July 1, presents some unique challenges for pharmaceutical and medical device manufacturers.
“This is the most robust anti-kickback, anti-payment, compliance plan, disclosure, and mandatory set of obligations of this sort anywhere in the country,” says Mark Schreiber, Esq., a partner with Edwards, Angell, Dodge, and Palmer in Boston and head of the firm’s Privacy Group.
Download our free white paper, Massachusetts Disclosure Regulations: New Challenges for Pharmaceutical, Medical Device Manufacturers, to learn more about the new law.
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- Case Management Monthly, March 2012
- Searched
